Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $5 Price Target

Benzinga Newsdesk www.benzinga.com Negative 56.7%

Neg 56.7% Neu 0% Pos 0%

Wedbush analyst David Nierengarten reiterates TScan Therapeutics (NASDAQ:TCRX) with a Outperform and maintains $5 price target.